Virtual Library
Start Your Search
Y. Liu
Author of
-
+
P2.02 - Biology/Pathology (ID 616)
- Event: WCLC 2017
- Type: Poster Session with Presenters Present
- Track: Biology/Pathology
- Presentations: 1
- Moderators:
- Coordinates: 10/17/2017, 09:30 - 16:00, Exhibit Hall (Hall B + C)
-
+
P2.02-033 - The Association of PD-L1 Expression with Clinical Characteristics and EGFR and ALK Status in Lung Adenocarcinoma (ID 8842)
09:30 - 16:00 | Author(s): Y. Liu
- Abstract
Background:
Programmed cell death-1 (PD-1) inhibitor is one of important medicines of immunotherapy for cancers. Programmed cell death ligand-1 (PD-L1) expression is a valuable predictor for selection of patients by PD-1 inhibitors therapy. However, the correlation of PD-L1 expression with clinicopathologic features, EGFR and ALK status, and prognosis of lung adenocarcinoma remain controversial.
Method:
421 lung adenocarcinoma patients with identified EGFR and ALK status in tumor tissues were enrolled. Using tissue microarrays, PD-L1 expression was evaluated using clone SP263 antibody by immunohistochemistry (IHC) on Ventana Benchmark automated staining system. The association of PD-L1 expression with clinicopathologic characteristics, EGFR and ALK status and prognosis of lung adenocarcinoma were analysed.
Result:
A total of 404 patients were available for evaluation. The positve incidence of PD-L1 expression was 22.5% (91/404) (using a cutoff of ≥ 25%). Multivariate Logistic regression analysis showed PD-L1 expression was associated with advanced stage (ORR 2.190, 95% CI 1.313-3.651, P = 0.003), solid predominant subtype (ORR 3.594, 95% CI 1.826-7.073, P < 0.001), and wild-type epidermal growth factor receptor (EGFR) (ORR 1.895, 95% CI 1.091-3.291, P = 0.023), while it was not associated with ALK rearrangement. In multivariate analysis for OS by Cox hazard proportion model, patients with early stage (HR 2.495, 95% CI 2.003-3.106, P < 0.001) and EGFR mutations (HR 1.635, 95% CI 1.310-2.040, P < 0.001) had a significantly longer survival, while PD-L1 expression was not associated with OS of patients with lung adenocarcinoma (HR 0.847, 95% CI 0.655-1.094, P = 0.203).
Conclusion:
Positive PD-L1 expression in lung adenocarcinoma tissues was significantly associated with tumor advanced stage, solid predominant subtype, and wild-type EGFR, however, PD-L1 expression may not be a predictor of OS for patients with lung adenocarcinoma.
-
+
P3.03 - Chemotherapy/Targeted Therapy (ID 719)
- Event: WCLC 2017
- Type: Poster Session with Presenters Present
- Track: Chemotherapy/Targeted Therapy
- Presentations: 1
- Moderators:
- Coordinates: 10/18/2017, 09:30 - 16:00, Exhibit Hall (Hall B + C)
-
+
P3.03-004 - The Frequency and Clinical Implication of ALK, ROS1, RET and NTRK1 Gene Rearrangements in Adenosquamous Lung Carcinoma Patients (ID 8254)
09:30 - 16:00 | Author(s): Y. Liu
- Abstract
Background:
Adenosquamous lung carcinoma (ASC) is a hybrid tumor made of adenocarcinoma and squamous cell carcinoma in one tumor. It is a rare disease with poorer prognosis comparing with the other common variants of non-small cell lung cancer (NSCLC). There is a persisting need for identifying more effective targeted therapy methods. Our previous study had examined the EGFR mutation status in lung ASC, the results showed that its mutation rate is similar with that of lung adenocarcinoma. Because the rarity of lung ASC, little is known about its gene rearrangement status and its relationship with the clinical characteristics.
Method:
ALK, ROS1, RET and NTRK1 gene rearrangement in lung ASC were examined by next generation sequencing methods, and further confirmed by fluorescent in situ hybridization (FISH) and/or immunohistochemistry methods. Tissue microarrays (TMAs) containing formalin fixed paraffin embedded (FFPE) lung ASC cases were used in this study.
Result:
This study included 53 cases of lung ASC totally. ALK/EML4 gene rearrangement was detected in 3 cases (5.7%), ROS1 fusion gene was detected in 1 cases (1.9%), RET gene rearrangement was detected in 1 case (1.9%). One of the ALK/EML4 rearrangement case had a concurrent EGFR exon 21 L858R mutation. All the rearrangement results can be further confirmed by FISH and/or immunohistochemistry methods. No association were identified between ALK/EML4 rearrangement and patient age, tumor size, clinical stage, positive pleural invasion, lymphovascular invasion, smoking status, lymph node metastasis, therapy methods, recurrence free survival (RFS) time or overall survival duration.
Conclusion:
The gene rearrangement rate of lung ASC is similar with that of lung adenocarcinoma, which further support our suggestion that lung ASC is a peculiar subtype of lung adenocarcinoma with a poorer prognosis than lung adenocarcinoma.
